SCHEMBL23628906

SCHEMBL23628906

COc1ccc(COC(=O)c2ccc3nc(NC(=O)c4c(Cl)c(Cl)c(C)n4C(C)C)sc3c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCD O00767 10/20 0.52
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
SMN1; SMN2 Q16637 5/20 0.49
KDM4E B2RXH2 3/20 0.49
MAPT P10636 2/20 0.49
ALDH1A1 P00352 3/20 0.49
CSNK1D P48730 3/20 0.48
GSK3B P49841 1/20 0.47
USP2 O75604 1/20 0.47
TP53 P04637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HPGD P15428 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
STAT1 P42224 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23629015 0.88 NPC1 (0.53) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL23628931 0.86 SCD (0.51) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL23628924 0.81 HSD17B10 (0.56) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL23628959 0.79 GSK3B (0.54) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL23629019 0.76 GSK3B (0.55) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL23629027 0.73 GSK3B (0.52) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL23628984 0.73 SCD (0.60) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL23628930 0.72 MAPT (0.55) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL4932123 0.72 SCD (0.82) SCDNPC1RAB9AMEN1KMT2A
SCHEMBL23628893 0.72 CYP3A4 (0.66) NPC1RAB9ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria UNIVERZA V LJUBLJANI (SI) 2025-03-25 US disclosed
US-20210323957-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA UNIVERZA V LJUBLJANI (SI) 2021-10-21 US disclosed
EP-3847172-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA Univerza v Ljubljani (SI) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323957-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOP1, TOP2A, TOP2B SCD 3587/4885NPC1 4573/4885RAB9A 3897/4885
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria TOP1, TOP2A, TOP2B SCD 3373/4885NPC1 4546/4885RAB9A 3924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.